A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study.

Trial Profile

A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Aug 2017

At a glance

  • Drugs Abiraterone acetate (Primary)
  • Indications Advanced breast cancer; Prostate cancer
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 01 Mar 2017 Status changed from active, no longer recruiting to recruiting.
    • 11 May 2015 Planned End Date changed from 1 Apr 2015 to 1 Apr 2018 as reported by ClinicalTrials.gov record.
    • 11 May 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Apr 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top